Food and Drug Administration, HHS

- (2) Indications for use—(i) For synchronization of estrus in suckled beef cows and replacement beef and dairy heifers, for advancement of first postpartum estrus in suckled beef cows, and for advancement of first pubertal estrus in replacement beef heifers.
- (ii) For synchronization of the return to estrus in lactating dairy cows inseminated at the immediately preceding estrus.
- (3) Limitations. Do not use in animals with abnormal, immature, or infected genital tracts; or in beef cows that are fewer than 20 days postpartum; or in beef or dairy heifers of insufficient size or age for breeding. Do not use an insert more than once. To prevent the potential transmission of venereal and bloodborne diseases, the inserts should be disposed after a single use. Administration of vaginal inserts for periods greater than 7 days may result in reduced fertility. Dinoprost solution as provided by No. 000009 in §510.600(c) of this chapter.

[67 FR 41824, June 20, 2002, as amended at 67 FR 51080, Aug. 7, 2002; 68 FR 57613, Oct. 6, 2003]

§529.2090 Salicylic acid.

- (a) *Specifications.* (1) Each dose contains 0.55 grain of salicylic acid in a gum arabic and dextrin vehicle.
- (2) Each dose is incorporated upon a device (teat dilator) suitable for insertion into and subsequent removal from the teat canal.
- (b) Sponsor. See No. 045087 in $\S510.600$ (c) of this chapter.
- (c) *Conditions of use.* (1) The drug is used for the removal of scar tissue in the teat canal of milk-producing cows.
- (2) The labeling bears directions to the user to:
- (i) Treat lactating cows initially by inserting dosage and removal of the device:
- (ii) Insert second dose and permit device to remain in canal until the next milking; and
- (iii) Insert one dose following each milking for not more than 2 days.

- (3) Milk that has been drawn from animals within 48 hours of such treatment may not be used for food.
- [41 FR 10984, Mar. 15, 1976, as amended at 43 FR 29290, July 7, 1978; 55 FR 29842, July 23, 1990; 55 FR 31481, Aug. 2, 1990; 62 FR 8372, Feb. 25, 1997]

§529.2150 Sevoflurane.

- (a) *Specifications.* The drug is a clear, colorless, stable liquid containing no additives or chemical stabilizers.
- (b) Sponsor. See No. 000074 in \$510.600(c) of this chapter.
- (c) Conditions of use—(1) Amount. For induction of surgical anesthesia: 5 to 7 percent sevoflurane with oxygen. For maintenance of surgical anesthesia: 3.7 to 4 percent sevoflurane with oxygen in the absence of premedication and 3.3 to 3.6 percent in the presence of premedication.
- (2) *Indications for use.* For induction and maintenance of general anesthesia in dogs.
- (3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[64 FR 71640, Dec. 22, 1999]

§529.2464 Ticarcillin powder.

- (a) Specifications. Each vial contains ticarcillin disodium equivalent to 6 grams of ticarcillin to be reconstituted with 25 milliliters of sterile water for injection or sterile physiological saline
- (b) *Sponsor*. See No. 000069 ir §510.600(c) of this chapter.
- (c) *Conditions of use*—(1) *Amount.* 6 grams per day, intrauterine, for 3 consecutive days during estrus.
- (2) Indications for use. Horses. Intrauterine treatment of endometritis caused by beta-hemolytic streptococci.
- (3) *Limitations*. For intrauterine use in horses only. Infuse aseptically. Not for use in horses raised for food production. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37336, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]

§ 529.2503 Tricaine methanesulfonate.

(a) *Chemical name.* Ethyl-*m*-aminobenzoate methanesulfonate.

Pt. 530

- (b) *Sponsor*. See Nos. 050378 and 051212 in §510.600(c) of this chapter.
- (c) Conditions of use. (1) It is used for the temporary immobilization of fish, amphibians, and other aquatic coldblooded animals (poikilotherms) as an aid in handling during manual spawning (fish stripping), weighing, measuring, marking, surgical operations, transport, photography, and research.

(2) It is used as follows:

- (i) For fish the drug is added to ambient water at a concentration of from 15 to 330 milligrams per liter depending upon the degree of anesthetization or sedation desired, the species and size of the fish, and the temperature and softness of the water. Preliminary tests of solutions must be made with small numbers of fish to determine the desired rates of sedation or anesthesia and the appropriate exposure times for the specific lots of fish under prevailing conditions.
- (ii) For amphibians and other aquatic coldblooded animals, the drug is added to ambient water in concentrations of from 1:1000 to 1:20,000 depending upon species and stage of development.
- (iii) Do not use within 21 days of harvesting fish for food. Use in fish intended for food should be restricted to Ictaluridae, Salmonidae, Esocidae, and Percidae, and water temperature should exceed 10 °C. (50 °F.). In other fish and in cold-blooded animals, the drug should be limited to hatchery or laboratory use.

[40 FR 13881, Mar. 27, 1975, as amended at 49 FR 5748, Feb. 15, 1984; 51 FR 11439, Apr. 3, 1986; 63 FR 7702, Feb. 17, 1998]

PART 530—EXTRALABEL DRUG USE IN ANIMALS

Subpart A—General Provisions

Sec.

530.1 Scope.

530.2 Purpose.

530.3 Definitions.

530.4 Advertising and promotion.

530.5 Veterinary records.

Subpart B—Rules and Provisions for Extralabel Uses of Drugs in Animals

530.10 Provision permitting extralabel use of animal drugs.

530.11 Limitations.

530.12 Labeling.

530.13 Extralabel use from compounding of approved new animal and approved human drugs.

Subpart C—Specific Provisions Relating to Extralabel Use of Animal and Human Drugs in Food-Producing Animals

- 530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals.
- 530.21 Prohibitions for food-producing animals.
- 530.22 Safe levels and analytical methods for food-producing animals.
- 530.23 Procedure for setting and announcing safe levels.
- 530.24 Procedure for announcing analytical methods for drug residue quantification.
 530.25 Orders prohibiting extralabel uses for drugs in food-producing animals.

Subpart D—Extralabel Use of Human and Animal Drugs in Animals Not Intended for Human Consumption

530.30 Extralabel drug use in nonfood animals.

Subpart E—Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals

530.40 Safe levels and availability of analytical methods.

530.41 Drugs prohibited for extralabel use in animals.

AUTHORITY: 15 U.S.C. 1453, 1454, 1455; 21 U.S.C. 321, 331, 351, 352, 353, 355, 357, 360b, 371, 379e.

Source: 61 FR 57743, Nov. 7, 1996, unless otherwise noted.

Subpart A—General Provisions

§ 530.1 Scope.

This part applies to the extralabel use in an animal of any approved new animal drug or approved new human drug by or on the lawful order of a licensed veterinarian within the context of a valid veterinary-client-patient relationship.

§530.2 Purpose.

The purpose of this part is to establish conditions for extralabel use or intended extralabel use in animals by or on the lawful order of licensed veterinarians of Food and Drug Administration approved new animal drugs and approved new human drugs. Such use is limited to treatment modalities when